SEC Form 4 · accession 0001181186-26-000008
Tarsus Pharmaceuticals, Inc. · TARS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wendy L Yarno
Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 4:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001819790
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 15, 2026 | M | 302 | — | A | 16,956 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F3 | — | Sep 15, 2026 | M | 302 | D | — | — | Common Stock | 302 | 907 | D |
Explanation of responses
- F1The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- F2Each RSU represents a contingent right to receive one share of the Company's common stock.
- F3RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.